Related Experiment Video

Updated: Sep 23, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Anti-epidermal growth factor receptor strategies to enhance radiation action

G Lammering1

  • 1Department of Radiation Oncology, University Clinic Duesseldorf, Heinrich-Heine University Duesseldorf, Germany. Guido.Lammering@uni-duesseldorf.de

Current Medicinal Chemistry. Anti-Cancer Agents
|July 23, 2003
PubMed

Insights

Targeting epidermal growth factor receptor (EGFR) alongside radiation therapy shows promise for cancer treatment. Further research is needed to confirm the efficacy of combined EGFR blockade and radiation in clinical settings.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) signaling is crucial for tumor growth, progression, and metastasis.
  • EGFR plays a key role in cancer cell survival and proliferation following ionizing radiation.
  • EGFR modulation is explored as a strategy to enhance radiation therapy efficacy.

Purpose of the Study:

  • To review anti-EGFR strategies aimed at modulating radiation response.
  • To discuss the biological rationale and preclinical evidence for combining EGFR blockade with radiation.
  • To highlight the need for further investigation into combined treatment modalities.

Main Methods:

  • Review of preclinical studies and radiobiological investigations.
  • Analysis of anti-EGFR strategies and their interaction with radiation.
  • Examination of current clinical trial data for EGFR inhibitors combined with radiation.

Main Results:

  • EGFR blockade demonstrates a favorable biological interaction with radiation in preclinical models.
  • EGFR inhibition can counteract cytoprotective and pro-proliferative effects of radiation.
  • Clinical data on combined EGFR inhibition and radiation is still emerging.

Conclusions:

  • EGFR is a significant target for enhancing radiation efficacy in cancer therapy.
  • Combined anti-EGFR strategies and radiation show potential but require further preclinical validation.
  • Establishing the definitive clinical role of EGFR inhibition with radiation necessitates more extensive research.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...